- Home
- OSUR vs ELDN Comparison
OSUR vs ELDN Comparison
Compare OSUR & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSUR
- ELDN
- Stock Information
- Founded
- OSUR 2000
- ELDN 2004
- Country
- OSUR United States
- ELDN United States
- Employees
- OSUR N/A
- ELDN N/A
- Industry
- OSUR Medical/Dental Instruments
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- OSUR Health Care
- ELDN Health Care
- Exchange
- OSUR Nasdaq
- ELDN Nasdaq
- Market Cap
- OSUR 223.0M
- ELDN 178.4M
- IPO Year
- OSUR 1986
- ELDN N/A
- Fundamental
- Price
- OSUR $2.99
- ELDN $3.23
- Analyst Decision
- OSUR Hold
- ELDN Strong Buy
- Analyst Count
- OSUR 2
- ELDN 1
- Target Price
- OSUR $5.50
- ELDN $16.00
- AVG Volume (30 Days)
- OSUR 624.9K
- ELDN 223.4K
- Earning Date
- OSUR 05-07-2025
- ELDN 05-08-2025
- Dividend Yield
- OSUR N/A
- ELDN N/A
- EPS Growth
- OSUR N/A
- ELDN N/A
- EPS
- OSUR N/A
- ELDN N/A
- Revenue
- OSUR $185,827,000.00
- ELDN N/A
- Revenue This Year
- OSUR N/A
- ELDN N/A
- Revenue Next Year
- OSUR $7.55
- ELDN N/A
- P/E Ratio
- OSUR N/A
- ELDN N/A
- Revenue Growth
- OSUR N/A
- ELDN N/A
- 52 Week Low
- OSUR $2.69
- ELDN $2.00
- 52 Week High
- OSUR $5.59
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- OSUR 43.10
- ELDN 53.49
- Support Level
- OSUR $2.84
- ELDN $3.27
- Resistance Level
- OSUR $3.10
- ELDN $3.56
- Average True Range (ATR)
- OSUR 0.15
- ELDN 0.24
- MACD
- OSUR 0.02
- ELDN 0.08
- Stochastic Oscillator
- OSUR 37.50
- ELDN 77.89
About OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.